CD36 rs1761667 Polymorphism and Its Impact on Molecular Signatures in Bladder Cancer.

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Bladder cancer is a complex disease with emerging genetic links.
• CD36, a scavenger receptor, is involved in lipid metabolism and tumor progression.
• The role of CD36 genetic variants in bladder cancer is unexplored.

Purpose of the Study:

• To investigate the association between the rs1761667 single nucleotide polymorphism and CD36 mRNA expression levels.
• To explore the potential impact of CD36 genetic variation on bladder cancer pathogenesis.

Main Methods:

• Genotyping of the rs1761667 variant using PCR-RFLP in 30 bladder cancer patients and 19 controls.
• Quantification of CD36 mRNA expression via RT-qPCR.
• Statistical analysis of genotype-expression correlations using the 2^-ΔΔCt method.

Main Results:

• CD36 mRNA expression significantly differed among rs1761667 genotypes in bladder cancer patients.
• AA genotype carriers exhibited reduced CD36 expression compared to GG carriers (p=0.03).
• No significant genotype-dependent expression differences were found in controls, and genotype distributions did not differ between cases and controls.

Conclusions:

• The rs1761667 variant may influence CD36 transcription in a genotype-dependent manner within the context of bladder cancer.
• These findings suggest a potential link between inherited CD36 variations and bladder cancer-related biological pathways.
• Further validation in tumor tissues is warranted to confirm these results.